Auris Medical Holding is a biotechnology business based in the US. Auris Medical Holding shares (EARS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.39 – the same closing value as a week prior. Auris Medical Holding employs 8 staff and has a trailing 12-month revenue of around $174,475.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.39 |
|---|---|
| 52-week range | $0.00 - $0.00 |
| 50-day moving average | $3.25 |
| 200-day moving average | $3.41 |
| Wall St. target price | $14.95 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.48 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.39 from 2021-09-24
| 1 week (2024-10-06) | N/A |
|---|---|
| 1 month (2024-09-13) | N/A |
| 3 months (2024-07-13) | N/A |
| 6 months (2024-04-13) | N/A |
| 1 year (2023-10-13) | N/A |
|---|---|
| 2 years (2022-10-13) | N/A |
| 3 years (2021-10-13) | N/A |
| 5 years (2019-10-17) | 23.83% |
| Revenue TTM | $174,475 |
|---|---|
| Gross profit TTM | $174,475 |
| Return on assets TTM | -21.99% |
| Return on equity TTM | -71.91% |
| Profit margin | 0% |
| Book value | $1.47 |
| Market Capitalization | $39.2 million |
TTM: trailing 12 months
We're not expecting Auris Medical Holding to pay a dividend over the next 12 months.
Auris Medical Holding's shares were split on a 1:20 basis on 30 April 2019. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Auris Medical Holding shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Auris Medical Holding shares which in turn could have impacted Auris Medical Holding's share price.
Over the last 12 months, Auris Medical Holding's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Auris Medical Holding's is 1.4048. This would suggest that Auris Medical Holding's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Auris Medical Holding Ltd. , a clinical-stage biopharmaceutical company, developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy, and CNS disorders. The company's Phase 3 programs under the development include Keyzilen (AM-101) for the treatment of acute inner ear tinnitus; and Sonsuvi (AM-111) for the treatment of acute inner ear hearing loss. It is also developing AM-125 that is in Phase 2 clinical trial for the intranasal treatment of acute peripheral vertigo; AM-201, which has completed Phase 1b clinical trial for the prevention of antipsychotic induced weight gain and drowsiness; and AM-301, a drug-free nasal spray for protection against airborne viruses and allergens, as well as AM-102 for the tinnitus treatment. The company has a collaboration and license agreement with INSERM; and Xigen S. A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.